---
title: "Ellie Kam and Danny O'Shea Shine in Winter Olympics Pairs Free Skate"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275234443.md"
description: "Ellie Kam and Danny O'Shea excelled in the Winter Olympics pairs free skate, delivering a flawless routine that has positioned them as strong gold medal contenders. Their performance, noted by the New York Times, showcased precision and artistry, potentially enhancing Team USA's standing in the competition. This success highlights their dedication and hard work leading up to the Olympics."
datetime: "2026-02-08T19:00:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275234443.md)
  - [en](https://longbridge.com/en/news/275234443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275234443.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275234443.md) | [繁體中文](https://longbridge.com/zh-HK/news/275234443.md)


# Ellie Kam and Danny O'Shea Shine in Winter Olympics Pairs Free Skate

Ellie Kam and Danny O'Shea delivered an exceptional performance in the pairs free skate at the Winter Olympics, showcasing their skills on the ice. New York Times posted on X, highlighting the significance of their flawless routine. Historically, pairs skating has been a challenging area for Team USA, but Kam and O'Shea's performance may have positioned them as strong contenders for the gold medal. Their routine was marked by precision and artistry, potentially elevating the United States' standing in the competition. The duo's success reflects the dedication and hard work that have characterized their journey to the Olympics.

## 相关资讯与研究

- [Rusoro Mining (CVE:RML) Director Sells 60,000 Shares](https://longbridge.com/zh-CN/news/281694931.md)
- [Should Record 2025 Output and 100% U.S. Reserve Replacement Require Action From Freehold (TSX:FRU) Investors?](https://longbridge.com/zh-CN/news/281696598.md)
- [Wasion Holdings Limited (3393) Gets a Buy from China Renaissance](https://longbridge.com/zh-CN/news/281702521.md)
- [Global Prosperity Sticks to Their Buy Rating for Fufeng Group Limited (FFO1)](https://longbridge.com/zh-CN/news/281702206.md)
- [CICC Sticks to Their Buy Rating for Ascentage Pharma Group International (6855)](https://longbridge.com/zh-CN/news/281702933.md)